Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
6 The mechanism by which esketamine exerts its antidepressant effect is unknown. Backed by more than a decade of research and almost six years of real-world evidence, SPRAVATO® has proven to be a ...
Spravato targets the neurotransmitter glutamate; however, the mechanism by which esketamine exerts its antidepressant effect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback